LABORATORY CORPORATION OF AMERICA HOLDINGS FORWARD-LOOKING STATEMENTSLaboratory Corporation of America® Holdings together with its subsidiaries (the Company) has made in this report, and from time to time may otherwise make in its public filings, press releases and discussions by Company management, forward-looking statements concerning the Company's operations, performance and financial condition, as well as its strategic objectives. Some of these forward-looking statements relate to future events and expectations and can be identified by the use of forward-looking words such as "believes", "expects", "may", "will", "should", "seeks", "approximately", "intends", "plans", "estimates", or "anticipates" or the negative of those words or other comparable terminology. Such forward-looking statements speak only as of the time they are made and are subject to various risks and uncertainties and the Company claims the protection afforded by the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those currently anticipated due to a number of factors in addition to those discussed elsewhere herein, including in the "Risk Factors" section of the Annual Report on Form 10-K, and in the Company's other public filings, press releases, and discussions with Company management, including: 1. changes in government and third-party payer regulations, reimbursement, or coverage policies or other future reforms in theU.S. healthcare system (or in the interpretation of current regulations), new insurance products or payment systems, including state, regional or private insurance cooperatives (e.g., health insurance exchanges) affecting governmental and third-party coverage or reimbursement for commercial laboratory testing, including the impact of theU.S. Protecting Access to Medicare Act of 2014 (PAMA); 2. significant monetary damages, fines, penalties, assessments, refunds, repayments, damage to the Company's reputation, unanticipated compliance expenditures, and/or exclusion or debarment from or ineligibility to participate in government programs, among other adverse consequences, arising from enforcement of anti-fraud and abuse laws and other laws applicable to the Company in jurisdictions in which the Company conducts business; 3. significant fines, penalties, costs, unanticipated compliance expenditures and/or damage to the Company's reputation arising from the failure to comply with applicable privacy and security laws and regulations, including theU.S. Health Insurance Portability and Accountability Act of 1996, theU.S. Health Information Technology for Economic and Clinical Health Act, theEuropean Union's General Data Protection Regulation and similar laws and regulations in jurisdictions in which the Company conducts business; 4. loss or suspension of a license or imposition of fines or penalties under, or future changes in, or interpretations of applicable licensing laws or regulations regarding the operation of clinical laboratories and the delivery of clinical laboratory test results, including, but not limited to, theU.S. Clinical Laboratory Improvement Act of 1967 and theU.S. Clinical Laboratory Improvement Amendments of 1988 and similar laws and regulations in jurisdictions in which the Company conducts business; 5. penalties or loss of license arising from the failure to comply with applicable occupational and workplace safety laws and regulations, including theU.S. Occupational Safety and Health Administration requirements, theU.S. Needlestick Safety and Prevention Act, and similar laws and regulations in jurisdictions in which the Company conducts business; 6. fines, unanticipated compliance expenditures, suspension of manufacturing, enforcement actions, damage to the Company's reputation, injunctions, or criminal prosecution arising from failure to maintain compliance with current good manufacturing practice regulations and similar requirements of various regulatory agencies in jurisdictions in which the Company conducts business; 7. sanctions or other remedies, including fines, unanticipated compliance expenditures, enforcement actions, injunctions or criminal prosecution arising from failure to comply with the Animal Welfare Act or applicable national, state and local laws and regulations in jurisdictions in which the Company conducts business; 8. changes in testing guidelines or recommendations by government agencies, medical specialty societies and other authoritative bodies affecting the utilization of laboratory tests; 9. changes in applicable government regulations or policies affecting the approval, availability of, and the selling and marketing of diagnostic tests, drug development, or the conduct of drug development and medical device and diagnostic studies and trials, including regulations and policies of theU.S. Food and Drug Administration , theU.S. Department of Agriculture , the Medicine and Healthcare products Regulatory Agency in theUnited Kingdom (U.K. ), theNational Medical Products Administration inChina , thePharmaceutical and Medical Devices Agency inJapan , theEuropean Medicines Agency and similar regulations and policies of agencies in other jurisdictions in which the Company conducts business; 21
--------------------------------------------------------------------------------
INDEX
10. changes in government regulations or reimbursement pertaining to the
biopharmaceutical and medical device and diagnostic industries, changes in
reimbursement of biopharmaceutical products, or reduced spending on research and
development by biopharmaceutical and medical device and diagnostic customers;
11. liabilities that result from the failure to comply with corporate
governance requirements;
12. increased competition, including price competition, potential reduction in
rates in response to price transparency and consumerism, competitive bidding
and/or changes or reductions to fee schedules and competition from companies
that do not comply with existing laws or regulations or otherwise disregard
compliance standards in the industry;
13. changes in payer mix or payment structure or processes, including
insurance carrier participation in health insurance exchanges, an increase in
capitated reimbursement mechanisms, the impact of clearinghouses on the claims
reimbursement process, the impact of a shift to consumer-driven health plans or
plans carrying an increased level of member cost-sharing, and adverse changes in
payer reimbursement or payer coverage policies (implemented directly or through
a third-party utilization management organization) related to specific
diagnostic tests, categories of testing or testing methodologies;
14. failure to retain or attract managed care organization (MCO) business as a
result of changes in business models, including risk-based or network
approaches, out-sourced laboratory network management or utilization management
companies, or other changes in strategy or business models by MCOs;
15. failure to obtain and retain new customers, an unfavorable change in the
mix of testing services ordered, or a reduction in tests ordered, specimens
submitted or services requested by existing customers, and delays in payment
from customers;
16. consolidation and convergence of customers, competitors, and suppliers,
potentially causing material shifts in insourcing, utilization, pricing,
reimbursement and supply chain access;
17. failure to effectively develop and deploy new systems, system modifications
or enhancements required in response to evolving market and business needs;
18. customers choosing to insource services that are or could be purchased from
the Company;
19. failure to identify, successfully close, and effectively integrate and/or
manage acquisitions of new businesses or failure to maintain key customers
and/or employees as a result of uncertainty surrounding the integration of
acquisitions;
20. inability to achieve the expected benefits and synergies of newly-acquired
businesses, including due to items not discovered in the due diligence process,
and the impact on the Company's cash position, levels of indebtedness and stock
price;
21. termination, loss, delay, reduction in scope or increased costs of
contracts, including large contracts and multiple contracts;
22. liability arising from errors or omissions in the performance of testing
services, contract research services, or other contractual arrangements;
23. changes or disruption in the provision or transportation of services or
supplies provided by third parties; or their termination for failure to follow
the Company's performance standards and requirements;
24. damage or disruption to the Company's facilities;
25. damage to the Company's reputation, loss of business, or other harm from
acts of animal rights activists or potential harm and/or liability arising from
animal research activities;
26. adverse results in litigation matters;
27. inability to attract and retain experienced and qualified personnel or the
loss of significant personnel as a result of illness or otherwise;
28. failure to develop or acquire licenses for new or improved technologies,
such as point-of-care testing, mobile health technologies, and digital
pathology, or potential use of new technologies by customers and/or consumers to
perform their own tests;
29. substantial costs arising from the inability to commercialize newly
licensed tests or technologies or to obtain appropriate coverage or
reimbursement for such tests;
30. failure to obtain, maintain and enforce intellectual property rights for
protection of the Company's products and services and defend against challenges
to those rights;
22--------------------------------------------------------------------------------
INDEX
31. scope, validity and enforceability of patents and other proprietary rights held by third parties that may impact the Company's ability to develop, perform, or market the Company's products or services or operate its business; 32. business interruption, receivable impairment, delays in cash collection impacting days sales outstanding, supply chain disruptions, increases in operating costs, or other impacts on the business due to natural disasters, including adverse weather, fires and earthquakes, political crises, including terrorism and war, public health crises and disease epidemics and pandemics, and other events outside of the Company's control; 33. discontinuation or recalls of existing testing products; 34. a failure in the Company's information technology systems, including with respect to testing turnaround time and billing processes, or the failure of the Company or its third-party suppliers and vendors to maintain the security of business information or systems or to protect against cybersecurity attacks such as denial of service attacks, malware, ransomware and computer viruses, or delays or failures in the development and implementation of the Company's automation platforms, any of which could result in a negative effect on the Company's performance of services, a loss of business or increased costs, damages to the Company's reputation, significant litigation exposure, an inability to meet required financial reporting deadlines, or the failure to meet future regulatory or customer information technology, data security and connectivity requirements; 35. business interruption, increased costs, and other adverse effects on the Company's operations due to the unionization of employees, union strikes, work stoppages, general labor unrest or failure to comply with labor or employment laws; 36. failure to maintain the Company's days sales outstanding levels, cash collections (in light of increasing levels of patient responsibility), profitability and/or reimbursement arising from unfavorable changes in third-party payer policies, payment delays introduced by third party utilization management organizations, and increasing levels of patient payment responsibility; 37. impact on the Company's revenues, cash collections and the availability of credit for general liquidity or other financing needs arising from a significant deterioration in the economy or financial markets or in the Company's credit ratings byStandard & Poor's and/or Moody's; 38. failure to maintain the expected capital structure for the Company, including failure to maintain the Company's investment grade rating, or leverage ratio covenants under its revolving credit facility; 39. changes in reimbursement by foreign governments and foreign currency fluctuations; 40. inability to obtain certain billing information from physicians, resulting in increased costs and complexity, a temporary disruption in receipts and ongoing reductions in reimbursements and revenues; 41. expenses and risks associated with international operations, including, but not limited to, compliance with theU.S. Foreign Corrupt Practices Act, theU.K. Bribery Act, other applicable anti-corruption laws and regulations, trade sanction laws and regulations, and economic, political, legal and other operational risks associated with foreign jurisdictions; 42. failure to achieve expected efficiencies and savings in connection with the Company's business process improvement initiatives; 43. changes in tax laws and regulations or changes in their interpretation; 44. global economic conditions and government and regulatory changes, including, but not limited to those arising from heU.K.'s exit from theEuropean Union ; and 45. effects, duration, and severity of the ongoing COVID-19 pandemic, including the impact on operations, personnel, supplies, liquidity, collections, and the actions the Company, or governments, have taken or may take in response, and damage to the Company's reputation or loss of business resulting from the perception of the Company's response to the COVID-19 pandemic, including the availability and accuracy and timeliness of delivery of any tests that the Company develops, collaborates on or provides for the detection of COVID-19, and the availability and timeliness of its drug development services.
Except as may be required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Given these uncertainties, one should not put undue reliance on any forward-looking statements.
23--------------------------------------------------------------------------------
INDEX
GENERAL (dollars in millions, except per share data)
Revenues for the three months endedMarch 31, 2021 , were$4,161.5 , an increase of 47.4% from$2,823.8 during the three months endedMarch 31, 2020 . The increase in revenues was due to organic growth of 45.1%, acquisitions of 0.9%, and favorable foreign currency translation of 1.4%. The 45.1% increase in organic revenue includes a 32.9% contribution from COVID-19 Testing and a 12.2% increase in the Company's organic Base Business. Base Business includes the Company's business operations except for PCR and antibody COVID-19 testing (COVID-19 Testing). The Company defines organic growth as the increase in revenue excluding revenue from acquisitions for the first twelve months after the close of each acquisition. While the Company continues to see strong momentum across its operations, the Company's board of directors and its management team believe that the Company's value is not appropriately reflected in its current stock price. InMarch 2021 , the Company announced that its board of directors and management had commenced a review of the Company's structure and capital allocation strategy to ensure that it is best positioned to unlock shareholder value while the Company continues to support patients and customers around the world. The board of directors has engagedGoldman Sachs & Co. LLC as its financial advisor to support the process. There can be no assurances regarding the outcome or timing of the review process. The Company does not undertake any obligation to provide updates on this process until a conclusion is reached.
RESULTS OF OPERATIONS (dollars in millions)
Three months endedMarch 31, 2021 , compared with three months endedMarch 31, 2020 Revenues Three Months Ended March 31, 2021 2020 Change Dx$ 2,757.8 $ 1,702.0 62.0 % DD 1,438.2 1,143.8 25.7 % Intercompany eliminations and other (34.5) (22.0) 56.8 % Total$ 4,161.5 $ 2,823.8 47.4 % The increase in revenues for the three months endedMarch 31, 2021 , as compared with the corresponding period in 2020 was 47.4%. The increase in revenues was due to organic growth of 45.1%, acquisitions of 0.9%, and favorable foreign currency translation of 1.4%. The 45.1% increase in organic revenue includes the 32.9% contribution from COVID-19 Testing and a 12.2% increase in the Company's organic Base Business. Dx revenues for the quarter were$2,757.8 , an increase of 62.0% compared to revenues of$1,702.0 in the first quarter of 2020. The increase in revenues was primarily due to organic growth of 60.8%, acquisitions of 0.9%, and favorable foreign currency translation of 0.4%. The 60.8% in organic revenue was due to a 54.5% contribution from COVID-19 Testing and a 6.3% increase in the Base Business, which includes the negative impact of weather of 2.0%. Total volume, measured by requisitions, increased by 27.3% as organic volume increased by 26.6% and acquisition volume contributed 0.7%. The organic volume growth was due to a 27.9% contribution from COVID-19 Testing, partially offset by a 1.3% reduction in revenue days. Price increased by 34.7% due to COVID-19 Testing of 26.6%, organic Base Business of 7.5%, favorable foreign currency translation of 0.4% and acquisitions of 0.2%. DD revenues for the first quarter were$1,438.2 , an increase of 25.7% over revenues of$1,143.8 in the first quarter of 2020. The increase in revenues was primarily due to organic growth of 21.9%, acquisitions of 1.0%, and favorable foreign currency translation of 2.9%. The 21.9% increase in organic revenue was due to a 19.7% increase in the Base Business and a 2.2% contribution from COVID-19 Testing performed through itsCentral Laboratories business. While continuing to be negatively impacted by the pandemic, DD benefited from broad-based demand across all service lines, including COVID-19 vaccine and therapeutic work. Cost of Revenues Three Months Ended March 31, 2021 2020 Change Cost of revenues$ 2,562.5 $ 2,095.8 22.3 % Cost of revenues as a % of revenues 61.6 %
74.2 %
Cost of revenues increased 22.3% during the three months endedMarch 31, 2021 , as compared with the corresponding period in 2020. Cost of revenues as a percentage of revenues during the three months endedMarch 31, 2021 , decreased to 24
--------------------------------------------------------------------------------
INDEX
61.6% as compared to 74.2% in the corresponding period in 2020. This decrease was primarily due to the impact of COVID-19 Testing, organic Base Business growth, and acquisitions, partially offset by higher personnel costs. Selling, General and Administrative Expenses
Three Months
Ended
2021 2020 Change
Selling, general and administrative expenses $ 429.8 $ 395.5 8.7 %
Selling, general and administrative expenses as a % of revenues
10.3 % 14.0 %
During the three months ended March 31, 2021 , the Company incurred $5.6 of
acquisition and divestiture related costs, $2.3 in COVID-related costs and $2.3
in management transition costs. In addition, the Company recorded $1.3 of
non-capitalized costs associated with the implementation of a major system as
part of its LaunchPad business process improvement initiative and $(2.4) related
to miscellaneous other items. These items increased selling, general and
administrative expenses by $9.1 .
During the three months ended March 31, 2020 , the Company incurred $8.4 in
acquisition and divestiture costs and $2.8 in management transition costs. In
addition, the Company recorded $0.9 of non-capitalized costs associated with the
implementation of a major system as part of its LaunchPad business process
improvement initiative and reversed $0.6 related to miscellaneous other items.
These items increased selling, general and administrative expenses by $11.9 .
Excluding these charges, selling, general and administrative expenses as a
percentage of revenues were 10.1% and 13.5% during the three months ended
March 31, 2021 , and 2020, respectively, primarily due to leveraging the
Company's infrastructure on higher revenue.
Goodwill and Other Asset Impairments
Three Months Ended March 31,
2021 2020 Change
Goodwill and other asset impairments $ - $
437.4 N/A
During the three months endedMarch 31, 2020 , the Company recorded goodwill and other asset impairment charges of$437.4 ,$426.4 within DD and$11.0 within Dx, representing 3.7% of the Company's total goodwill and intangible assets. The Company concluded that the fair value was less than carrying value for certain of its reporting units and recorded goodwill impairment of$418.7 in DD and$3.7 in Dx. The Company also recorded a charge of$2.7 for the impairment of a DD tradename,$7.3 for Dx software and$5.0 for the impairment of the DD floating rate secured note receivable due in 2022. There were no goodwill and other asset impairments for the three months endedMarch 31, 2021 . Amortization of Intangibles and Other Assets Three Months Ended March 31, 2021 2020 Change Dx $ 28.1$ 26.2 7.3 % DD 64.0 36.1 77.3 %
Total amortization of intangibles and other assets $ 92.1
$ 62.3 47.8 % The increase in amortization of intangibles and other assets primarily reflects the impact of acquisitions occurring afterMarch 31, 2020 , and$29.2 of accelerated amortization related to the Covance trade name as a result a rebranding initiative, partially offset by lower amortization due to the impairment of intangible assets in 2020. Restructuring and Other Special Charges Three Months Ended March 31, 2021 2020 Change Restructuring and other charges $ 19.2 $
25.4 (24.4) %
During the three months endedMarch 31, 2021 , the Company recorded net restructuring and other charges of$19 .2:$7.5 within Dx and$11.7 within DD. The charges were comprised of$4.2 related to severance and other personnel costs and$15.1 in facility closures, lease terminations, and general integration activities. The charges were offset by the reversal of a previously established liability of$0.1 in unused facility-related costs. During the three months endedMarch 31, 2020 , the Company recorded net restructuring and other special charges of$25 .4:$8.1 within Dx and$17.3 within DD. The charges were comprised of$5.1 related to severance and other personnel costs,$4.7 for a DD lab facility impairment, and$15.8 in costs associated with facility closures, impairment of operating lease right-of-use assets, and general integration initiatives. The charges were offset by the reversal of previously established reserves of$0.2 in unused facility reserves. 25
--------------------------------------------------------------------------------
INDEX
Interest Expense
Three Months Ended March 31,
2021 2020 Change
Interest expense $ (48.5) $ (55.0) (11.8) %
The decrease in interest expense for the three months ended March 31, 2021 , as
compared with the corresponding period in 2020, is primarily due to the
repayment of the 4.625% senior notes and the 2019 Term Loan.
Equity Method Income
Three Months Ended March 31,
2021 2020 Change
Equity method income, net $ 4.5 $ (6.6) (168.2) %
Equity method income represents the Company's ownership share in joint venture
partnerships along with equity investments in other companies in the health care
industry. All of these partnerships and investments reside within Dx. The
increase in income for the three months ended March 31, 2021 , as compared with
the corresponding period in 2020, was primarily due the write off or write down
of certain of the Company's investments in 2020 primarily due to the negative
impact of the COVID-19 global pandemic and increased profitability of the
Company's joint ventures in 2021.
Other, net
Three Months Ended March 31,
2021 2020 Change
Other, net $ 5.5 $ (16.1) (134.2) %
The change in other, net for the three months ended March 31, 2021 , as compared
to the three months ended March 31, 2020 , is primarily due to the write off or
write down of certain of the Company's investments in 2020 primarily due to the
negative impact of the COVID-19 global pandemic as compared to net investment
gains in 2021. In addition, foreign currency transaction losses of $1.0 were
recognized for the three months ended March 31, 2021 , and losses of $2.8 were
recognized in the corresponding period of 2020.
Income Tax Expense
Three Months Ended March 31,
2021 2020 Change
Income tax expense $ 251.7 $ 49.2 411.6 %Income tax expense as a % of earnings before income taxes
24.6 % (18.4) %
The 2021 tax rate was favorable to the 2020 tax rate due primarily to the 2020
impairment charges for which either no tax benefit was recorded (as they were
not deductible) or the associated tax assets required a full valuation
allowance.
Operating Income by Segment
Three Months Ended March 31,
2021 2020 Change
Dx operating income $ 949.1 $ 205.2 $ 743.9
Dx operating margin 34.4 % 12.1 % 22.3 %
DD operating income (loss) 156.4 (338.7) $ 495.1
DD operating margin 10.9 % (29.6) % 40.5 %
General corporate expenses (47.6) (59.1) 11.5
Total operating income (loss) $ 1,057.9 $ (192.6) Dx operating income was$949.1 for the three months endedMarch 31, 2021 , an increase of$743.9 over operating income of$205.2 in the corresponding period of 2020, and Dx operating margin increased 2,230 basis points year-over-year. The increase was primarily due to the increase in COVID-19 Testing, organic Base Business growth and LaunchPad savings, partially offset by higher personnel costs. The Company remains on track to deliver approximately$200.0 of net savings from its three-year Dx LaunchPad initiative by the end of 2021. DD operating income was$156.4 for the three months endedMarch 31, 2021 , an increase over operating loss of$338.7 in the corresponding period of 2020. The increase was primarily due to goodwill and other asset impairments in 2020 and in 2021 organic Base Business growth, COVID-19 Testing, and LaunchPad savings, partially offset by higher personnel costs. The Company continues to develop and execute new LaunchPad programs to support profitable growth in DD. General corporate expenses are comprised primarily of administrative services such as executive management, human resources, legal, finance, corporate affairs, and information technology. Corporate expenses were$47.6 for the three months 26
--------------------------------------------------------------------------------
INDEX
endedMarch 31, 2021 , a decrease of$11.5 over corporate expenses of$59.1 in the corresponding period of 2020, primarily due to higher executive transition costs in 2020. LIQUIDITY AND CAPITAL RESOURCES (dollars and shares in millions) The Company's strong cash-generating ability and financial condition typically have provided ready access to capital markets. The Company's principal source of liquidity is operating cash flow, supplemented by proceeds from debt offerings. The Company's senior unsecured revolving credit facility is further discussed in Note 7 Debt to the Company's Condensed Consolidated Financial Statements. In summary, the Company's cash flows were as follows for the three months endedMarch 31, 2021 , and 2020, respectively:
Three Months Ended
2021 2020
Net cash provided by operating activities $ 1,157.6 $ 203.8
Net cash used for investing activities (132.4) (106.6)
Net cash used for financing activities (450.1) (102.8)
Effect of exchange rate changes on cash and cash equivalents (5.1) (8.3)
Net increase (decrease) in cash and cash equivalents $
570.0
Cash and Cash Equivalents Cash and cash equivalents atMarch 31, 2021 , and 2020, totaled$1,890.8 and$323.6 , respectively. Cash and cash equivalents consist of highly liquid instruments, such as time deposits, commercial paper, and other money market investments, substantially all of which have original maturities of three months or less. Operating Activities During the three months endedMarch 31, 2021 , the Company's operations provided$1,157.6 of cash as compared to$203.8 during the same period in 2020. The$953.8 increase in cash provided from operations in 2021 as compared with the corresponding 2020 period is primarily due to higher cash earnings and lower working capital. Investing Activities Net cash used for investing activities for the three months endedMarch 31, 2021 , was$132.4 as compared to net cash used for investing activities of$106.6 for the three months endedMarch 31, 2020 . The change in cash used for investing activities was primarily due to an increase in business acquisitions during the three months endedMarch 31, 2021 partially offset by lower capital expenditures. Capital expenditures were$95.4 and$106.6 for the three months endedMarch 31, 2021 , and 2020, respectively. Financing Activities Net cash used for financing activities for the three months endedMarch 31, 2021 , was$450.1 compared to$102.8 for the three months endedMarch 31, 2020 . The change in cash flows from financing activities for the three months endedMarch 31, 2021 , as compared to the three months endedMarch 31, 2020 , were primarily due to repayment of the 2019 Term Loan inFebruary 2021 , partially offset by a$31.5 reduction in share repurchases. OnApril 30, 2021 , the Company amended and restated its revolving credit facility. It consists of a five-year revolving facility in the principal amount of up to$1,000.0 , with the option of increasing the facility by up to an additional$500.0 (which was previously$350.0 ), subject to the agreement of one or more new or existing lenders to provide such additional amounts and certain other customary conditions. The Company is required to pay a facility fee on the aggregate commitments under the revolving credit facility, at a per annum rate ranging from 0.100% to 0.225% (which was a per annum rate ranging from 0.100% to 0.25% prior to the amendment and restatement), depending on the Company's debt ratings. Borrowings under the revolving credit facility will accrue interest at a per annum rate equal to, at the Company's election, either (x) a LIBOR rate plus a margin ranging from 0.775% to 1.275% or (y) a base rate plus a margin ranging from 0% to 0.275%, in each case, depending on the Company's debt ratings. Under the Company's revolving credit facility, the Company is subject to negative covenants limiting subsidiary indebtedness and certain other covenants typical for investment grade-rated borrowers and the Company is required to maintain certain leverage ratios. The Company was in compliance with all covenants under the revolving credit facility atMarch 31, 2021 , and expects that it will remain in compliance with its existing debt covenants for the next twelve months. InFebruary 2021 , the Company fully repaid the remaining$375.0 of the 2019 Term Loan. AtMarch 31, 2021 , the Company had$1,890.8 of cash and$1,000.0 of available borrowings under its revolving credit facility, which does not mature until 2026. 27
--------------------------------------------------------------------------------
INDEX
As ofMarch 31, 2021 , the Company had outstanding authorization from the board of directors to purchase up to$731.5 of the Company's common stock. The repurchase authorization has no expiration date. Credit Ratings The Company's investment grade debt ratings from Moody's and from Standard and Poor's (S&P) contribute to its ability to access capital markets. The Company's expectation is that it will seek to maintain an investment grade debt rating regardless of what, if anything, results from the Company's current review of its structure and capital allocation strategy. ITEM 3. Quantitative and Qualitative Disclosures about Market Risk (dollars in millions) Market risk is the potential loss arising from adverse changes in market rates and prices, such as foreign currency exchange rates, interest rates, and other relevant market rate or price changes. In the ordinary course of business, the Company is exposed to various market risks, including changes in foreign currency exchange and interest rates, and the Company regularly evaluates its exposure to such changes. The Company addresses its exposure to market risks, principally the market risks associated with changes in foreign currency exchange rates and interest rates, through a controlled program of risk management that includes, from time to time, the use of derivative financial instruments such as foreign currency forward contracts, and interest rate and cross currency swap agreements. Foreign Currency Exchange Rates Approximately 14.0% of the Company's revenues for the three months endedMarch 31, 2021 , and approximately 12.8% of the Company's revenue for the three months endedMarch 31, 2020 , were denominated in currencies other than theU.S. dollar. The Company's financial statements are reported inU.S. dollars and, accordingly, fluctuations in exchange rates will affect the translation of revenues and expenses denominated in foreign currencies intoU.S. dollars for purposes of reporting the Company's consolidated financial results. In the first quarter of 2021 and the year endedDecember 31, 2020 , the most significant currency exchange rate exposures were to the Canadian dollar, Swiss Franc, Euro and British Pound. Excluding the impacts from any outstanding or future hedging transactions, a hypothetical change of 10% in average exchange rates used to translate all foreign currencies toU.S. dollars would have impacted income before income taxes for the three months endedMarch 31, 2021 , by approximately$6.7 . Gross accumulated currency translation adjustments recorded as a separate component of shareholders' equity were$(66.8) and$(147.5) atMarch 31, 2021 , and 2020, respectively. The Company does not have significant operations in countries in which the economy is considered to be highly-inflationary. The Company earns revenue from service contracts over a period of several months and, in some cases, over a period of several years. Accordingly, exchange rate fluctuations during this period may affect the Company's profitability with respect to such contracts. The Company is also subject to foreign currency transaction risk for fluctuations in exchange rates during the period of time between the consummation and cash settlement of transactions. The Company limits its foreign currency transaction risk through exchange rate fluctuation provisions stated in some of its contracts with customers, or it may hedge transaction risk with foreign currency forward contracts. AtMarch 31, 2021 , the Company had 30 open foreign exchange forward contracts relating to service contracts with various amounts maturing monthly throughApril 2021 with a notional value totaling approximately$672.2 . AtDecember 31, 2020 , the Company had 31 open foreign exchange forward contracts relating to service contracts with various amounts maturing monthly throughJanuary 2021 with a notional value totaling approximately$601.2 . The Company is party toU.S. Dollar to Swiss Franc cross-currency swap agreements with an aggregate notional amount of$600.0 , maturing in 2022 and 2025, as a hedge against the impact of foreign exchange movements on its net investment in a Swiss Franc functional currency subsidiary. Interest Rates Some of the Company's debt from time to time is subject to interest at variable rates. As a result, fluctuations in interest rates can affect the business. The Company attempts to manage interest rate risk and overall borrowing costs through an appropriate mix of fixed and variable rate debt including by the utilization of derivative financial instruments, primarily interest rate swaps. Borrowings under the Company's term loan credit facility, now repaid, and revolving credit facility are subject to variable interest rates, unless fixed through interest rate swaps or other agreements. As ofMarch 31, 2021 , andDecember 31, 2020 , the Company had$0.0 and$375.0 , respectively, of unhedged variable debt from the 2019 term loan credit facility and$0.0 and$0.0 , respectively, outstanding on its revolving credit facility. ITEM 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures As of the end of the period covered by this Quarterly Report on Form 10-Q, the Company carried out, under the supervision and with the participation of the Company's management, including the Company's principal executive officer and principal financial officer, an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and 28
--------------------------------------------------------------------------------
INDEX
procedures (as defined in Rules13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Based upon this evaluation, the Company's principal executive officer and principal financial officer concluded that the Company's disclosure controls and procedures were effective as ofMarch 31, 2021 . Changes in Internal Control Over Financial Reporting There were no changes in the Company's internal control over financial reporting (as defined in Rules13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) that occurred during the quarter endedMarch 31, 2021 , that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. 29
--------------------------------------------------------------------------------
INDEX
LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES
© Edgar Online, source
